Previous 10 | Next 10 |
NetworkNewsWire Editorial Coverage : Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable. Gene therapy is the next great leap forward in medicine, with several noteworthy programs u...
Quick Take Hookipa Pharma ( HOOK ) has filed proposed terms to raise $100 million in a U.S. IPO, per an amended registration statement . Hookipa is advancing a pipeline of immunotherapeutics for infectious diseases and cancers. HOOK has generated promising trial results for its lead can...
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for bluebird bio's (NASDAQ: BLUE ) Lentiglobin gene therapy, branded as Zynteglo, for the treatment adolescents and adults with transfusion-dependent β-thalassaemia who do not ha...
First gene therapy recommended for approval in the EU for TDT Treatment with ZYNTEGLO has been shown to help eliminate the need for chronic blood transfusions in patients with TDT ZYNTEGLO is bluebird bio’s first gene therapy submitted for regulatory approval bluebird bio,...
(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...
Bluebird bio (NASDAQ: BLUE ) officially opens its first wholly owned manufacturing facility in Durham, N.C., that will produce lentiviral vector for the company’s investigational gene and cell therapies, including: bb2121 and bb21217 for the treatment of multiple myeloma and potenti...
Gov. Cooper to cut ribbon on facility that will strengthen bluebird bio's capabilities to manufacture products for clinical development and commercial supply bluebird bio, Inc. (Nasdaq: BLUE) today announced the official opening of its first wholly owned manufacturing facility in Durh...
Certain gene therapy stocks are up premarket in reaction to Roche's $4.8B bid for Spark Therapeutics. More news on: bluebird bio, Inc., Solid Biosciences, Inc., CRISPR Therapeutics, Healthcare stocks news, Stocks on the move, , Read more ...
Bluebird bio (NASDAQ: BLUE ) Q4 result s ($M): 18.4 (+357.1%). More news on: bluebird bio, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...